Brent Meadows

BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY.

CardioGenics, Inc. manufactures biotechnology and medical devices. It develops in-vitro-diagnostics cardiac testing products. The company was founded in 1997 and is headquartered in Mississauga, Canada.

Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada.

Ernst & Young LLP (Canada) engages in the provision of consulting, assurance, tax, and transaction services. The company is headquartered in Toronto, Canada.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

Axcelon Biopolymers Corp. provides medical devices for human health applications. It provides devices to those companies which uses nanotechnology to biodegradable polymer design and applications. Its technology includes stent coating, ophthalmology, drug delivery and regenerative medicine. The company is headquartered in Toronto, Canada

Mcmaster Innovation Park operates as a premier research park that offers collaborative space for researchers and entrepreneurs to co-locate, connect and commercialize. The company is headquartered in Hamilton, Canada.

Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Harbour Biomed Shanghai Co. Ltd. engages in the development of therapeutics for cancer, especially in immuno-oncology. The company is headquartered in Shanghai, China.

Triumvira Immunologics USA, Inc. develops and manufactures novel T cell therapies for cancer. The company is based in Austin, TX and has subsidiaries in Canada. Paul Lammers has been the CEO of the company since 2018.